Although Pfizer's and Moderna’s COVID-19 vaccines have been stealing the spotlight for years, some people are actively ...

US biotech Novavax has begun a phase 1 study of its coronavirus vaccine, as the number in clinical development reached double figures. The World Health Organization has been keeping tabs on ...

New COVID-19 vaccines should roll out in the fall ... Updated COVID-19 vaccines will be rolled out from Moderna, Novavax, and ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

A clinical trial has found that Novavax’ COVID-19 vaccine ... and should read out in a few weeks. UK Health Secretary Matt Hancock has previously said that approval of the vaccine would be ...

Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and COVID-19 cases in the U.S. following the latest ...

Federal funding for COVID-19 ... COVID-19 vaccine to match, NACI said. The most recent mRNA vaccines, manufactured by Pfizer-BioNTech and Moderna, target the KP.2 Omicron subvariant. Novavax ...

Federal funding for COVID-19 ... COVID-19 vaccine to match, NACI said. The most recent mRNA vaccines, manufactured by Pfizer-BioNTech and Moderna, target the KP.2 Omicron subvariant. Novavax ...

What Else: Novavax stands out for its non-mRNA approach to combating infectious diseases. The company's flagship product, Nuvaxovid, a COVID-19 vaccine, provides an alternative for individuals who ...